Positive news on bluebird bio's study of Lenti-D for boys with CALD

21 April 2016

US biotech bluebird bio (Nasdaq: BLUE) has announced encouraging data from a Phase II/III study of the impact of its Lenti-D product candidate in pediatric patients with cerebral adrenoleukodystrophy (CALD).

Also known as Lorenzo’s Oil disease, CALD is a rare and fatal, X-linked, inherited, neurodegenerative disease that primarily affects young boys. The disease involves a progressive destruction of myelin, the protective sheath of the nerve cells in the brain that are responsible for thinking and muscle control.

Lenti-D has been studied as an alternative to the existing imperfect treatment in the ongoing Starbeam Study (ALD-102), interim data from which has been presented at the American Academy of Neurology Annual Meeting.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK